Recent advances in cancer immunotherapy have shown that ICIs, including inhibitors of PD‐1, PD‐L1, CTLA‐4, LAG‐3, TIM‐3, and TIGIT, can improve the clinical response and survival of patients with a broad spectrum of metastatic cancers, such as melanoma, non‐small lung cancer, and renal cell cancer (Table 2).13, 369, 371, 374, 375, 376. The gene discussed is CTLA4; the disease is cancer.